Preventing mumps outbreaks in confined settings: Comprehensive ring vaccination as a containment strategy

Levine, Hagai; Rishpon, Shmuel; Huerta-Hartal, Michael; Davidovitch, Nadav

doi:10.4161/hv.7.12.18111

Cited by 21 publications

(10 citation statements)

References 17 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Such boosting of antibody titers would be useful during an outbreak in which the virus continues to circulate and future exposures are likely. If infection does occur, the postexposure vaccine dose may lead to milder clinical manifestations, lower complication rates, and shorter duration of virus shedding ( 15 ). …”

Section: Discussionmentioning

confidence: 99%

Mumps Postexposure Prophylaxis with a Third Dose of Measles-Mumps-Rubella Vaccine, Orange County, New York, USA

Fiebelkorn

Lawler²,

Curns³

et al. 2013

Emerg. Infect. Dis.

View full text Add to dashboard Cite

Although the measles-mumps-rubella (MMR) vaccine is not recommended for mumps postexposure prophylaxis (PEP), data on its effectiveness are limited. During the 2009–2010 mumps outbreak in the northeastern United States, we assessed effectiveness of PEP with a third dose of MMR vaccine among contacts in Orthodox Jewish households who were given a third dose within 5 days of mumps onset in the household’s index patient. We compared mumps attack rates between persons who received a third MMR dose during the first incubation period after onset in the index patient and 2-dose vaccinated persons who had not. Twenty-eight (11.7%) of 239 eligible household members received a third MMR dose as PEP. Mumps attack rates were 0% among third-dose recipients versus 5.2% among 2-dose recipients without PEP (p = 0.57). Although a third MMR dose administered as PEP did not have a significant effect, it may offer some benefits in specific outbreak contexts.

show abstract

Section: Discussionmentioning

confidence: 99%

Mumps Postexposure Prophylaxis with a Third Dose of Measles-Mumps-Rubella Vaccine, Orange County, New York, USA

Fiebelkorn

Lawler²,

Curns³

et al. 2013

Emerg. Infect. Dis.

View full text Add to dashboard Cite

show abstract

“…10 During 2009 -2010 the mumps outbreak extended to other districts in Israel, and later spread to the military sector, with over 5200 reported mumps cases country-wide. 9,11 We characterized the cases of mumps in Jerusalem that occurred during this outbreak, evaluated the association between the clinical severity of mumps (defined by mumps complications and hospitalization) and vaccination status (number of MMR vaccine doses received prior to the outbreak); and assessed the MMR vaccine effectiveness.…”

Section: Introductionmentioning

confidence: 99%

Characteristics of a large mumps outbreak: Clinical severity, complications and association with vaccination status of mumps outbreak cases

Stein‐Zamir

Schroeder

Shoob

et al. 2015

Human Vaccines & Immunotherapeutics

View full text Add to dashboard Cite

In recent years, large mumps outbreaks, involving mainly adolescents and young adults, have re-emerged in several countries. We investigated a large mumps outbreak, evaluated the association between mumps clinical severity (complications, hospitalization) and vaccination status (number of previous measles, mumps and rubella -MMR vaccine doses), and assessed vaccine effectiveness. The first mumps cases emerged in an ultra-orthodox boys' school in Jerusalem and were epidemiologically linked to the mumps outbreak in New York. Overall, 3130 mumps cases were notified in the Jerusalem district during September 2009-August 2011 (median age 13y, 64% males). Most cases were reported from community clinics. Patients with systemic symptoms and/or complications (419, 13.4%) were either hospitalized (n D 79) or treated in an emergency medical center (n D 340). The main complications included orchitis (3.8% males> age 12y) and meningoencephalitis (0.5%). The mumps virus genotype was G5. The distribution of previous MMR vaccine doses (n D 0,1,2) was: 24.8%, 28.3% and 46.9%, respectively. The number of previous vaccine doses was inversely associated with clinical severity. Adjusted values for MMR vaccine effectiveness against complications were estimated as 52.1% (95% CI ¡4 ¡78%) for one vaccine dose and 62.7% (95% CI 25.7-81.3%) for 2 doses. The outbreak was characterized by predominance of male students; the majority of whom had been previously vaccinated. The reported complication rate was relatively low. Vaccination status was associated with age and disease severity. The combination of limited mumps vaccine effectiveness and the specific school setting (dense learning and living conditions) probably contributed to the disease spread.

show abstract

“…A number of vaccination strategies have been used to control infectious diseases or have been considered as potential control options. [25][26][27][28][29][30][31][32] Vaccination strategies applicable to Ebola include the following:…”

Section: Aligning Vaccine Strategies With the Epidemiology Of Diseasementioning

confidence: 99%

The Ebola Vaccine Team B: a model for promoting the rapid development of medical countermeasures for emerging infectious disease threats

Osterholm

Moore

Ostrowsky

et al. 2016

The Lancet Infectious Diseases

View full text Add to dashboard Cite

In support of accelerated development of Ebola vaccines from preclinical research to clinical trials, in November, 2014, the Wellcome Trust and the Center for Infectious Disease Research and Policy (CIDRAP) at the University of Minnesota established the Wellcome Trust-CIDRAP Ebola Vaccine Team B initiative. This ongoing initiative includes experts with global experience in various phases of bringing new vaccines to market, such as funding, research and development, manufacturing, determination of safety and efficacy, regulatory approval, and vaccination delivery. It also includes experts in community engagement strategies and ethical issues germane to vaccination policies, including eight African scientists with direct experience in developing and implementing vaccination policies in Africa. Ebola Vaccine Team B members have worked on a range of vaccination programmes, such as polio eradication (Africa and globally), development of meningococcal A disease vaccination campaigns in Africa, and malaria and HIV/AIDS vaccine research. We also provide perspective on how this experience can inform future situations where urgent development of vaccines is needed, and we comment on the role that an independent, expert group such as Team B can have in support of national and international public health authorities toward addressing a public health crisis.

show abstract

Preventing mumps outbreaks in confined settings: Comprehensive ring vaccination as a containment strategy

Cited by 21 publications

References 17 publications

Mumps Postexposure Prophylaxis with a Third Dose of Measles-Mumps-Rubella Vaccine, Orange County, New York, USA

Mumps Postexposure Prophylaxis with a Third Dose of Measles-Mumps-Rubella Vaccine, Orange County, New York, USA

Characteristics of a large mumps outbreak: Clinical severity, complications and association with vaccination status of mumps outbreak cases

The Ebola Vaccine Team B: a model for promoting the rapid development of medical countermeasures for emerging infectious disease threats

Contact Info

Product

Resources

About